Proactive Investors - Run By Investors For Investors

Midatech says open offer oversubscribed, raises £13.4mln in aggregate from it, a placing and share subscription

The AIM-listed group said it received valid acceptances in respect of 20,870,414 open offer units, representing approximately 107% of the 19,456,554 units offered
Tumour
At the end of January, Midatech Pharma revealed that Chinese billionaire, Lam Kong was to acquire a 77.3% stake in the company for £8mln

Midatech Pharma PLC (LON:MTPH) (NASDAQ:MTP) said the open offer launched on 4 February together with a placing and share subscription, was oversubscribed with the firm raising £13.4mln in aggregate, before expenses,  from the offerings.

The AIM-listed group – which at the end of January revealed aid Chinese billionaire, Lam Kong a 77.3% stake in the company for £8mln – said it received valid acceptances in respect of 20,870,414 open offer units from qualifying shareholders, representing approximately 107% of the 19,456,554 units offered.

READ: Chinese billionaire invests £8mln in AIM drug developer Midatech

It added that, following scale-back, 100% of the 19,456,554 open offer units - comprising one new ordinary share and one warrant) - will be issued at a price of 3.85p each.

The company said all shareholders with valid applications will receive their full allocation of ordinary shares in respect of their basic entitlement, with excess shares allocated at the board’s absolute discretion.

Midatech added that all resolutions put to shareholders were duly passed at its general held earlier today in relation to the fund-raising.

The company also confirmed that, as previously announced, it completed its submission for a loan under the Spanish Ministry of Industry Reindustrialisation programme to cover up to 75% of the qualifying manufacturing scale-up cost, with the loan application outcome still expected to be known around the end of the first half of 2019.

In addition to this, the group added - as announced on 10 January 2019 – it has received approval for funding of €1.5mln for the company's manufacturing facility in Bilbao Spain.

The company confirmed that it received written confirmation from the Basque regional government on 7 January and that the loan finance is available upon submission of invoices by the company for validly incurred scale-up costs.

In said amounts drawn under the facility will be repayable from February 2022 at a rate of € 0.3mln per annum, with no interest in the facility.

View full MTPH profile View Profile

Midatech Pharma PLC Timeline

Related Articles

A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
patch
May 20 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use